One of the lessons to come out of the JUUL affair is that it can be dangerous to come up with a product that is ‘too’ successful.
Does the US Food and Drug Administration know what it’s doing? Presumably yes. Do its actions always promote public health? Apparently not. Is this concerning? It would seem so.
British American Tobacco says that, given the success of its next generation product portfolio, it will increase investments in these products during 2018.
It was clearly not possible for Philip Morris International to maintain forever the huge growth rate of heated-tobacco-product sales that it had enjoyed in Japan; but there is a world beyond Japan.
The Malaysian arm of British American Tobacco has put the launch of reduced risk products on hold while it sees which way the regulatory wind is blowing.
Those opposed to the excessive use of electronic cigarettes among young people should define what they mean by ‘excessive’ use and, therefore, what they think is acceptable use.
There are times when the US Food and Drug Administration could be accused of acting too slowly, but there are times also when it is necessary to stop and reflect.
In partnering in an event in London last night, Philip Morris International once again demonstrated that it is serious about encouraging smokers to switch to lower-risk products.
A replication study of emissions from e-liquids has provided results that are significantly different to those of the original study.
A change in government in New Zealand seems to have put a brake on a move to legalize vaping with nicotine, leaving smokers in a difficult place.